We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
from Part 3.6 - Molecular pathology: lymphoma and leukemia
Published online by Cambridge University Press: 05 February 2015
Introduction
Acute myeloid leukemia (AML) is an oligoclonal malignancy characterized by several differences from normal hematopoiesis, including blockade of normal differentiation, enhanced self-renewal, increased proliferation, impaired apoptosis, dissemination, and genomic instability. Recent advances in our understanding of the pathogenesis of AML have involved elucidation of the role of aberrant chromosomal rearrangement, amplifications, deletions, and point mutations, and aberrant regulation of gene expression, governed in part by changes in chromatin. AML can now be subclassified based upon gene mutations, gene expression, miRNA expression, and DNA methylation states, and many of the phenotypic properties of AML and alterations in gene expression can be mapped onto underlying genetic lesions. Within several years, a near complete categorization of AML will be achieved, and a variety of new therapeutic targets will be identified. Remaining challenges will be to understand the molecular mechanisms linking genetic and epigenetic changes to leukemia cell growth and the translation of these findings into specific therapies that may target mutant proteins or deregulated gene networks.
The evolving modes of classification of acute myeloid leukemia
The French-American-British (FAB) system classified acute myeloid leukemia (AML) by analogy to normal myelopoiesis, but yielded relatively poor information in that only a few subtypes, such as acute promyelocytic leukemia (APL), could be distinguished as having a distinct prognosis. Over the past two decades, conventional cytogenetics, flow cytometry, fluorescence in situ hybridization, DNA sequencing, and PCR have led to the definition of more precise subsets of AML with distinct prognoses. This was reflected in the 1999 WHO system that includes cytogenetic and molecular anomalies (1). The revolution in genomic technology will soon lead to a reassessment of AML and the definition of even smaller prognostic subsets.
To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Find out more about the Kindle Personal Document Service.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.
